World's Best Scientists 2026 revealed!
Chemical Biology and Drug Design
H-index 17

Chemical Biology and Drug Design

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Biology and Biochemistry 503 52 59 12
Chemistry 639 76 73 11

Additional Metrics

Number of Best Scientists*: 166
Documents by Best Scientists*: 145
Top 100 Ranked Scientists*: 7
SCIMAGO H-index: 96
SCIMAGO SJR: 0.689
Impact Factor: N/A

Overview

Top Research Topics at Chemical Biology & Drug Design?

Chemical Biology & Drug Design covers a variety of subjects, including Stereochemistry, Biochemistry, Pharmacology, Docking (molecular) and In vitro. The journal explores topics in Stereochemistry which can be helpful for research in disciplines like IC50, Structure–activity relationship and Active site. The study on Biochemistry presented is investigated in conjunction with research in Cell culture.

Pharmacology research is the primary subject tackled in it with a focus on Drug. Virtual screening is a major topic of Docking (molecular) research. Some problems in Virtual screening that were presented in the journal overlapped with concepts under Pharmacophore and Computational biology.

Research on Computational biology addressed in it frequently intersections with the field of Drug discovery. Chemical Biology & Drug Design dives deep in exploring the relationship between the study of In vitro and In vivo. The in-depth study on Peptide also explores topics in the intersecting field of Peptide sequence.

  • Stereochemistry (30.64%)
  • Biochemistry (27.31%)
  • Pharmacology (13.03%)

What are the most cited papers published in the journal?

  • The Future of Peptide‐based Drugs (1081 citations)
  • Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. (791 citations)
  • The Structure of Glycosaminoglycans and their Interactions with Proteins (694 citations)

Research areas of the most cited articles at Chemical Biology & Drug Design:

The journal papers mainly tackle studies in Biochemistry, Stereochemistry, Pharmacology, Drug discovery and Combinatorial chemistry. The most cited papers explore issues in Stereochemistry which can be linked to other research areas like Molecule and Active site. The Drug discovery research tackled in the published articles is interrelated with Computational biology which concerns subjects like In silico.

What topics the last edition of the journal is best known for?

  • Enzyme
  • Gene
  • Organic chemistry

The previous edition focused in particular on these issues:

Chemical Biology & Drug Design explores disciplines such as Pharmacology, Biochemistry, Stereochemistry, In vitro and Cancer research. The Pharmacology works featured in it incorporate elements from Inflammation, Oxidative stress and In vivo. Cytotoxicity, Enzyme and Peptide are some of the study areas of Biochemistry discussed.

In vitro research is concerned with IC50 in particular. Most of the works presented in it deals with IC50 but it intersects with the subject of Inhibitory postsynaptic potential. The research on Cancer research tackled can also make contributions to studies in the areas of Cancer cell, Cancer, Cell culture, Apoptosis and Kinase.

The most cited articles from the last journal are:

  • Antioxidant activities and mechanisms of polysaccharides. (11 citations)
  • Repurposing potential of FDA approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm. (6 citations)
  • 1,3,4‐oxadiazole and its derivatives: A review on recent progress in anticancer activities (6 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Chemical Biology & Drug Design (based on the number of publications) are:

  • Tomi K. Sawyer (27 papers) absent at the last edition,
  • Jürgen Bajorath (26 papers) absent at the last edition,
  • J. Andrew McCammon (22 papers) absent at the last edition,
  • Erik De Clercq (19 papers) published 1 paper at the last edition,
  • Hai Qian (18 papers) published 1 paper at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Chemical Biology & Drug Design (based on the number of publications) are:

  • China Pharmaceutical University (52 papers) published 2 papers at the last edition, 2 less than at the previous edition,
  • Chinese Academy of Sciences (50 papers) published 2 papers at the last edition, 2 less than at the previous edition,
  • Shandong University (42 papers) published 3 papers at the last edition, 1 more than at the previous edition,
  • Sichuan University (40 papers) published 3 papers at the last edition, 2 more than at the previous edition,
  • University of California, San Diego (38 papers) published 1 paper at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 6.77% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 11.17% were posted by at least one author from the top 10 institutions publishing in the journal. Another 3.91% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 14.53% of all publications and 70.39% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Top Publications

  • SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic

    (2022)
    90 Citations
  • Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.

    Jingyi Yang;Zhao Zhang;Fengyuan Yang;Fengyuan Yang;Haiwei Zhang

    (2021)
    43 Citations
  • Deciphering the detailed structure-activity relationship of coumarins as Monoamine oxidase enzyme inhibitors-An updated review.

    (2021)
    42 Citations
  • A review on computer‐aided chemogenomics and drug repositioning for rational COVID‐19 drug discovery

    (2022)
    41 Citations
  • Design, synthesis, and biological evaluation of piperidinyl‐substituted [1,2,4]triazolo[1,5‐a]pyrimidine derivatives as potential anti‐HIV‐1 agents with reduced cytotoxicity

    Boshi Huang;Dongwei Kang;Ye Tian;Dirk Daelemans

    (2021)
    26 Citations
  • Natural naphthoquinones and their derivatives as potential drug molecules against trypanosome parasites

    (2022)
    26 Citations
  • Computer‐Aided Drug Design of Small Molecule Inhibitors of the ERCC1‐XPF Protein‐Protein Interaction

    Francesco Gentile;Ahmed H. Elmenoufy;Ahmed H. Elmenoufy;Gloria Ciniero;Gloria Ciniero;David Jay

    (2020)
    23 Citations
  • Development of potent inhibitors by fragment‐linking strategies

    (2022)
    23 Citations

Related Online Degrees & Career Pathways

Studying Chemistry in the USA opens many doors to diverse career paths, often enhanced by specialized online degrees. For example, those interested in healthcare and pharmaceuticals might explore becoming a pharmacist, a career that requires understanding how long does it take to become a pharmacist, including the completion of advanced degrees and licensure.

Alternatively, chemistry graduates can transition into roles that blend science and business, such as pharmaceutical sales. Understanding the pharmaceutical sales salary and pathways is crucial for those aiming to enter this dynamic field.

For individuals interested in healthcare administration or medical coding, earning a certified professional coder certification online can be an excellent complement to a chemistry background, opening up well-paid, stable opportunities.

Lastly, chemistry graduates looking to expand into nursing might consider some of the best online BSN programs for non nurses, designed to fast-track entry into this rewarding healthcare profession. These flexible programs can build on a chemistry foundation to advance careers in patient care and beyond.

Best Scientists Contributing to This Journal